FDA Breakthrough Therapy Designation for Pompe disease drug
The FDA has granted Amicus’ AT-GAA a Breakthrough Therapy Designation (BTD) for the treatment of late onset Pompe disease.
Read More
Tag: Pompe
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
